FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Up 6.7% in November

FibroBiologics, Inc. (NASDAQ:FBLG) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 2,700,000 shares, an increase of 6.7% from the November 15th total of 2,530,000 shares. Approximately 10.2% of the shares of the stock are short sold. Based on an average trading volume of 376,500 shares, the short-interest ratio is presently 7.2 days.

FibroBiologics Stock Down 0.5 %

NASDAQ FBLG traded down $0.01 on Tuesday, reaching $2.15. The company had a trading volume of 126,416 shares, compared to its average volume of 246,959. The firm has a 50-day moving average of $2.77 and a 200-day moving average of $3.68. FibroBiologics has a 1 year low of $1.08 and a 1 year high of $55.00.

Institutional Trading of FibroBiologics

A number of institutional investors and hedge funds have recently made changes to their positions in FBLG. Fund Evaluation Group LLC bought a new stake in FibroBiologics during the second quarter worth approximately $5,265,000. Geode Capital Management LLC increased its holdings in shares of FibroBiologics by 90.0% in the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock valued at $1,854,000 after purchasing an additional 284,047 shares during the period. State Street Corp lifted its position in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after purchasing an additional 99,789 shares in the last quarter. Cascade Financial Partners LLC acquired a new position in shares of FibroBiologics in the second quarter worth $1,572,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of FibroBiologics by 5.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after purchasing an additional 3,451 shares in the last quarter.

Analyst Ratings Changes

FBLG has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of FibroBiologics in a research report on Wednesday, November 13th. Maxim Group assumed coverage on shares of FibroBiologics in a report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a “strong-buy” rating in a research note on Wednesday, September 4th. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $13.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.